Efficacy and Safety Study of SHR117887 in Combination With Metformin in Patients With Type 2 Diabetes

• Status: Completed
• Trial end date: 2013-08-01
• Target enrollment: 0
• Participant gender: All

Summary

SHR117887 is a new dipeptidyl peptidase(DPP)-4 inhibitor. This study aims to evaluate the efficacy and safety of SHR117887 in combination therapy with Metformin in patients with Type 2 Diabetes in Metformin monotherapy Who have Inadequate Glycemic Control

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.
• Treatments: Metformin

Criteria

Inclusion Criteria:

• Patients diagnosed with type 2 diabetes mellitus

• Patients have been treated with metformin for at least 8 weeks and be on a stable dose of at least 1500mg daily prior to the screening visit

• HbA1C：≥7.5% and ≤11.0% at screeing visit and at the end of run-in period

• Age:≥20 and ≤70 years

• BMI(body mass index):≥20 and ≤35 kg/m2

Exclusion Criteria:

-